7.450USD0.00%Mkt Cap: 14.77M USDP/E: —Last update: 2026-05-22
Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company develops FIN-211, a microbiome candidate …
Industry Peers
Biotechnology110.61BUSDP/E 25.8
106.49BDKKP/E 20.5
66.47BUSDP/E 15.5
46.51BEURP/E 30.5
43.17BEURP/E 35.9
39.41BUSDP/E 74.0
32.84BUSD—
31.18BSEKP/E 46.1
Indicators:|
Key Statistics
Company
Market Cap14.77M USD
Enterprise Value25.78M USD
Revenue (TTM)0 USD
Gross Profit0 USD
Net Income (TTM)-74.75M USD
Revenue/Share0.0000 USD
Last Price7.450 USD
Fiscal Year EndDec 2023
MR QuarterJun 2024
Employees1
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-0.45
PEG—
EV/EBITDA-1.32
EV/Revenue—
P/SInfinity
P/B1.04
EPS (TTM)-8.80
EPS (Forward)-20.59
52W Range
2.00039% of range16.10
52W High16.10 USD
52W Low2.000 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin-69863.55%
ROE-326.64%
ROA-135.00%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-31.50M USD
CapEx (TTM)—
FCF Margin—
FCF Yield-108.06%
Net Debt12.95M USD
Net Debt/EBITDA-0.66
Balance Sheet
Debt/Equity1.32
Current Ratio3.87
Quick Ratio3.59
Book Value/Sh8.855 USD
Cash/Share9.986 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:30
Split DateJun 12, 2023
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.1.61M
Float1.56M
Insiders3.40%
Institutions0.00%
Short Interest
Short Ratio0.2d
Short % Float2.76%
Short % Out.1.20%
Shares Short19.20K
Short (prev mo.)10.60K
Technical
SMA 5012.77 (-41.7%)
SMA 20012.96 (-42.5%)
Beta1.17
S&P 52W Chg28.31%
Avg Vol (30d)8.51K
Avg Vol (10d)16.38K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—